Drug Profile
NMI 8000
Alternative Names: Mullerian inhibitory substance - Nemucore; NMI-8000; rhMIS - NemucoreLatest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator Massachusetts General Hospital; Nemucore Medical Innovations
- Developer Massachusetts General Hospital; Nemucore Medical Innovations; Primrose Bio
- Class Proteins; Transforming growth factors
- Mechanism of Action Anti-Mullerian hormone receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gynaecological cancer; Ovarian cancer
Most Recent Events
- 18 Sep 2023 Primordial Genetics has merged with Pelican Expression Technology to form Primrose Bio
- 01 Oct 2020 Pfenex has been acquired by Ligand Pharmaceuticals
- 28 Jan 2020 No recent reports of development identified for preclinical development in Gynaecological-cancer in USA